HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

Peer Review reports

Original Submission
3 Nov 2015	Submitted	Original manuscript
9 Mar 2016	Author responded	Author comments - Kathy Miller
Resubmission - Version 2
9 Mar 2016	Submitted	Manuscript version 2
15 Mar 2016	Reviewed	Reviewer Report - Brian Van Tine
2 May 2016	Reviewed	Reviewer Report - Debra A. Tonetti
3 May 2016	Author responded	Author comments - Kathy Miller
3 May 2016	Reviewed	Reviewer Report - Cynthia Ma
Resubmission - Version 3
3 May 2016	Submitted	Manuscript version 3
Publishing
25 May 2016	Editorially accepted
3 Jun 2016	Article published	10.1186/s12885-016-2385-z

Back to article page